Disclaimer: GLP-1 Compensation is not a law firm. Nothing on this site constitutes legal advice. Learn more

Vision Loss · NAION · Canadian Case Review

Vision Loss After a GLP-1 Medication — Canadian Case Review

If you experienced sudden vision loss, including non-arteritic anterior ischemic optic neuropathy (NAION), while taking a GLP-1 medication in Canada, you can request a free case review. Submitting your information does not mean you qualify, and no outcome is guaranteed.

  • Free, no-obligation case review
  • No fees unless your case settles
  • All Canadian provinces and territories

13

Provinces & territories served

100%

Free case review

0

Upfront fees

Free Case Review — No Obligation

See If Your Experience May Qualify For Review

Answer a few quick questions. It takes about 2 minutes.

1
2
3

Step 1 of 3

Many Patients Are Still Looking For Answers

Reports involving GLP-1 medications have raised questions about serious digestive complications, including gastroparesis, bowel obstruction, and other gastrointestinal injuries. This review helps determine whether your experience may fit a pattern currently being investigated.

Which medication did you take? *

By submitting, you consent to be contacted about your claim and agree to our Privacy Policy & Terms.

Information last verified: October 23, 2026

What Is NAION?

Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition in which blood flow to the optic nerve is reduced, causing sudden, painless vision loss. It is the leading cause of acute optic neuropathy in older adults.

NAION can occur in people who have never taken a GLP-1 medication, so a diagnosis on its own does not show what caused it. Only a physician, typically an ophthalmologist, can diagnose it.

See symptoms and related side effects on our side effects page

What the Medical and Regulatory Evidence Shows

Research: A 2025 study published in JAMA Ophthalmology (Cai et al.) analysed 14 health databases covering 37.1 million adults with type 2 diabetes. It found a modest increase in the risk of NAION associated with semaglutide, smaller than previously reported, and concluded that the association warrants further investigation. The study was observational and reports an association. It does not establish that semaglutide causes NAION in any individual patient.

European Union, June 2025: The European Medicines Agency's safety committee (PRAC) concluded that NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus and Wegovy), meaning it may affect up to 1 in 10,000 people taking semaglutide. It recommended updating the product information and advised patients who experience sudden loss of vision or rapidly worsening eyesight to contact their doctor without delay.

Canada: The EMA decision applies to the European Union and is not a Health Canada decision. To see the current Canadian safety information for a specific medication, consult its product monograph in Health Canada's Drug Product Database or ask your pharmacist. Regulatory warnings and legal allegations are separate matters.

Canadian Proposed Class Actions

Status as published by Siskinds, verified October 23, 2026.

Siskinds LLP and Siskinds Desmeules have filed proposed class actions in Canada that list vision loss (non-arteritic anterior ischemic optic neuropathy) among the injuries alleged. A proposed class action is a lawsuit that a court has not yet authorized to proceed as a class action.

Novo Nordisk (semaglutide and liraglutide): A proposed class action naming Ozempic, Rybelsus, Wegovy, Saxenda and Victoza was filed in the Supreme Court of British Columbia on October 6, 2023 and amended on October 3, 2025. A related application naming Ozempic and Rybelsus was filed in the Superior Court of Quebec on November 6, 2023 and amended on February 6, 2026. The Quebec court stayed that application on July 22, 2024 to give precedence to the British Columbia action.

Eli Lilly (dulaglutide and tirzepatide): A proposed class action naming Trulicity, Mounjaro and Zepbound was filed in British Columbia on February 11, 2026. An application naming the same medications was filed in Quebec on December 23, 2025.

According to Siskinds, these proceedings are at an early stage and have not been authorized by a court. The allegations have not been proven. Nothing on this page means that a court has found that any medication caused any injury, or that compensation will be available.

If You Notice Sudden Vision Changes

If you experience sudden loss of vision or rapidly worsening eyesight, contact your doctor or seek urgent medical care without delay. Do not stop or change a prescribed medication without speaking to your prescriber. This page is not medical advice.

Helpful Records to Keep

Siskinds recommends that potential class members keep a record of their medical treatments and related expenses. If a legal service provider contacts you after your case review request, they may ask about items such as these:

  • Prescription records for the GLP-1 medication
  • Medical appointments and the health care providers you saw
  • Any diagnosis you were given, and by whom
  • Expenses related to your care

You do not need to upload medical records to request a case review.

Vision Loss and GLP-1 Medications: FAQ

Answers based on the sources listed above.

NAION (non-arteritic anterior ischemic optic neuropathy) is a condition in which reduced blood flow to the optic nerve causes sudden, painless vision loss. It is the leading cause of acute optic neuropathy in older adults and can occur in people who have never taken a GLP-1 medication.

Not conclusively. A 2025 observational study in JAMA Ophthalmology, covering 14 databases and 37.1 million adults with type 2 diabetes, found a modest increase in NAION risk associated with semaglutide and called for further investigation. An association in a population does not establish that a medication caused NAION in a particular person.

The EMA's June 2025 conclusion that NAION is a very rare side effect of semaglutide medicines applies to the European Union. It is not a Health Canada decision. For current Canadian safety information, consult the product monograph in Health Canada's Drug Product Database or ask your pharmacist.

Siskinds has filed proposed class actions in British Columbia and Quebec against Novo Nordisk and Eli Lilly that list vision loss (NAION) among the alleged injuries. According to Siskinds, they are at an early stage and have not been authorized by a court, and the allegations have not been proven. The Quebec application against Novo Nordisk was stayed on July 22, 2024 in favour of the British Columbia action.

Not necessarily. Taking a medication and experiencing vision loss does not by itself establish a legal claim. A case review looks at your individual circumstances. It is free and has no obligation, and no outcome is guaranteed.

Contact your doctor or seek urgent medical care without delay. Do not stop or change a prescribed medication without speaking to your prescriber. This site does not provide medical advice.

Request a Free Case Review

The case review is free and carries no obligation. Submitting your information does not mean you qualify for a claim, and no outcome is guaranteed.

  • You took Ozempic, Wegovy, or another GLP-1 medication
  • You experienced a serious side effect
  • You are a resident of Canada
  • You have not yet retained a lawyer for this matter
Start My Free Case Review

Free case review · No obligation · No upfront fees

Legal Notice

GLP-1 Compensation is a legal referral and intake service — not a law firm — and does not provide legal advice. No lawyer–client relationship is formed by submitting information, calling any number on this site, or any other communication with us; such a relationship arises only upon formal written retainer with a licensed lawyer. Information submitted may be shared with licensed legal professionals in our referral network for case review.

Individual results vary. Qualifying for a case review does not guarantee a valid legal claim, legal representation, or any compensation. All claims are subject to applicable provincial limitation periods and other legal requirements.

This page does not constitute medical advice and is not a substitute for professional healthcare guidance. Do not discontinue, modify, or adjust any prescribed GLP-1 medication — including Ozempic, Wegovy, or Mounjaro — without first consulting your prescribing physician or healthcare provider.

Information on this site is for general informational purposes only and should not be relied upon as legal advice or as a substitute for advice from a qualified lawyer licensed in your province or territory. This site is intended solely for Canadian residents.

Read our full disclaimer · Privacy Policy